What is CV Sciences?
CV Sciences is a diversified company operating in both the pharmaceutical and consumer products sectors. Its pharmaceutical division is dedicated to developing synthetically formulated cannabidiol (CBD) based medicines, actively pursuing U.S. Food and Drug Administration (FDA) approval for drugs targeting specific indications. Concurrently, the consumer products division offers botanical-based CBD products aimed at enhancing quality of life. Established in 2010 and headquartered in San Diego, California, CV Sciences is strategically focused on leveraging cannabidiol for therapeutic and wellness applications.
How much funding has CV Sciences raised?
CV Sciences has raised a total of $15.1M across 4 funding rounds:
Debt
$2M
Debt
$2M
Other Financing Round
$10M
Debt
$1.1M
Debt (2016): $2M, investors not publicly disclosed
Debt (2020): $2M led by PPP
Other Financing Round (2020): $10M supported by Tumim Stone Capital
Debt (2021): $1.1M, investors not publicly disclosed
Key Investors in CV Sciences
PPP
Public-Private Partnership
What's next for CV Sciences?
The substantial enterprise-level funding and recent strategic investment signal a pivotal phase for CV Sciences. This capital infusion is expected to accelerate the development and regulatory approval processes for its pharmaceutical pipeline, particularly its CBD-based drug candidates. Furthermore, the backing will likely support the expansion of its consumer products division, enhancing market reach and product innovation. CV Sciences appears poised to solidify its position as a key player in the burgeoning cannabis-derived therapeutics and wellness markets, driven by its dual-pronged approach to product development and market penetration.
See full CV Sciences company page
